Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM2 | Q14416 | 3/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6435524 | 0.91 | GRM2 (0.52) | GRM2CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL6433330 | 0.82 | GRM2 (0.69) | GRM2CYP3A4RAB9ASMN1; SMN2 | |
| SCHEMBL5563129 | 0.82 | GRM2 (0.54) | GRM2CYP3A4 | |
| SCHEMBL5869007 | 0.81 | GRM2 (0.51) | GRM2 | |
| SCHEMBL5558163 | 0.80 | GRM2 (0.55) | GRM2CYP3A4 | |
| SCHEMBL6437638 | 0.80 | GRM2 (0.46) | GRM2CYP3A4 | |
| SCHEMBL6433768 | 0.80 | GRM2 (0.53) | GRM2 | |
| SCHEMBL6433356 | 0.79 | GRM2 (0.80) | GRM2CYP3A4 | |
| SCHEMBL6435010 | 0.79 | GRM2 (0.47) | GRM2CYP3A4 | |
| SCHEMBL5868955 | 0.78 | CYP3A4 (0.61) | CYP3A4RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1379522-B1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | HOFFMANN LA ROCHE (CH) | 2005-01-26 | — | — | EP | disclosed |
| EP-1379522-A1 | DIHYDRO-BENZO(b)(1,4)DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| US-6548495-B2 | Metabotropic glutamate receptor agonist for treatment or prevention of acute and/or chronic neurological disorders | HOFFMANN-LA ROCHE INC. | 2003-04-15 | — | — | US | disclosed |
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | HOFFMANN-LA ROCHE INC. | 2002-12-26 | — | — | US | disclosed |
| WO-2002083665-A1 | DIHYDRO-BENZO[b][1,4]DIAZEPIN-2-ONE DERIVATIVES AS MGLUR2 ANTAGONISTS I | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020198197-A1 | Dihydro-benzo [b] [1,4] diazepin-2-one derivatives | BDKRB1, BDKRB2, GRIN1 | GRM2 73/4885CYP3A4 1411/4885RAB9A 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.